Interactions between glucocorticoids and cytokines in the bone microenvironment

被引:31
作者
Angeli, A
Dovio, A
Sartori, ML
Masera, RG
Ceoloni, B
Prolo, P
Racca, S
Chiappelli, F
机构
[1] Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy
[2] Univ Calif Los Angeles, Sch Dent, Lab Oral & Mol Immunol, Los Angeles, CA 90024 USA
来源
NEUROENDOCRINE IMMUNE BASIS OF THE RHEUMATIC DISEASES II, PROCEEDINGS | 2002年 / 966卷
关键词
IL-6; IL-11; glucocorticoid; glucocorticoid receptor; osteoblast; osteoclast; osteoporosis;
D O I
10.1111/j.1749-6632.2002.tb04207.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cytokines belonging to the so-called interleukin-6 (IL-6) or gp130 cytokine family, notably IL-6 and IL-11, are known as pro-resorptive cytokines, in that they promote osteoclastogenesis. Glucocorticoid (GC)-induced osteoporosis is admittedly the most frequent secondary osteoporosis. The pathogenesis still has many unresolved issues. Although the effects of GCs on cytokine production and recognition have been extensively studied, little is known about the effects of cytokines on GC action at the target level. We have focused on the effects of IL-6 and IL-11 on specific binding by type 11 GC receptors (GRs) in two human osteoblast-like cell lines (Saos-2 and MG-63) that have remarkably different constitutive expression of these cytokines and GRs as well. We have provided evidence that IL-6 upregulates GR binding sites, while IL-11 downregulates these sites, as determined by radioligand binding assay and Scatchard analysis. GR affinity (K-d) did not change after exposure to both cytokines. A number of experiments were consistent with the view that in human osteoblast-like cells, cytokines of the IL-6 family have autocrine modulatory effects on GRalpha (GRbeta is a variant that does not bind specifically in our method). Complex effects of GCs on the system(s) of proinflammatory/anti-inflammatory cytokines and conversely of these cytokines on GC action could account for the dynamics of bone loss in patients given GCs and conceivably having high concentrations of these cytokines in the bone microenvironment.
引用
收藏
页码:97 / 107
页数:11
相关论文
共 47 条
[21]   The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases [J].
Hofbauer, LC ;
Heufelder, AE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) :2355-2363
[22]   Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis [J].
Honda, M ;
Orii, F ;
Ayabe, T ;
Imai, S ;
Ashida, T ;
Obara, T ;
Kohgo, Y .
GASTROENTEROLOGY, 2000, 118 (05) :859-866
[23]   INCREASED OSTEOCLAST DEVELOPMENT AFTER ESTROGEN LOSS - MEDIATION BY INTERLEUKIN-6 [J].
JILKA, RL ;
HANGOC, G ;
GIRASOLE, G ;
PASSERI, G ;
WILLIAMS, DC ;
ABRAMS, JS ;
BOYCE, B ;
BROXMEYER, H ;
MANOLAGAS, SC .
SCIENCE, 1992, 257 (5066) :88-91
[24]   Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss [J].
Kim, CH ;
Cheng, SL ;
Kim, GS .
JOURNAL OF ENDOCRINOLOGY, 1999, 162 (03) :371-379
[25]   Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling [J].
Li, H ;
Wang, HL ;
Nicholas, J .
JOURNAL OF VIROLOGY, 2001, 75 (07) :3325-3334
[26]  
Lin SC, 1996, J BONE MINER RES, V11, pP281
[27]   THE MODULATION OF THE EXPRESSION OF IL-6 AND ITS RECEPTOR IN HUMAN OSTEOBLASTS INVITRO [J].
LITTLEWOOD, AJ ;
RUSSELL, J ;
HARVEY, GR ;
HUGHES, DE ;
RUSSELL, RGG ;
GOWEN, M .
ENDOCRINOLOGY, 1991, 129 (03) :1513-1520
[28]   Low glucocorticoid receptor α/β ratio in T-cell lymphoblastic leukemia [J].
Longui, CA ;
Vottero, A ;
Adamson, PC ;
Cole, DE ;
Kino, T ;
Monte, O ;
Chrousos, GP .
HORMONE AND METABOLIC RESEARCH, 2000, 32 (10) :401-406
[29]   Molecular control of immune/inflammatory responses: Interactions between nuclear factor-κB and steroid receptor-signaling pathways [J].
McKay, LI ;
Cidlowski, JA .
ENDOCRINE REVIEWS, 1999, 20 (04) :435-459
[30]   Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis [J].
Moreland, L ;
Gugliotti, R ;
King, K ;
Chase, W ;
Weisman, M ;
Greco, T ;
Fife, R ;
Korn, J ;
Simms, R ;
Tesser, J ;
Hillson, J ;
Caldwell, J ;
Schnitzer, T ;
Lyons, D ;
Schwertschlag, U .
ARTHRITIS RESEARCH, 2001, 3 (04) :247-252